Abstract. The expression levels of 16 proteins were analyzed to identify prognostic correlations in esophageal squamous cell carcinoma (ESCC) treated with concurrent chemoradiation therapy (CCRT). The immunohistochemical expression levels of p53, p21\textsuperscript{waf1}, molecular immunology borstel-1 (MIB-1, Ki-67), p16\textsuperscript{INK4A}, cyclin D1, E-cadherin, Bcl-2, tumor necrosis factor (TNF)-\textgreek{a}, NF-\textk{B}, TGF-\textgreek{B}, MMP-7, COX-2, EGFR, HER2/neu, ER, and HIF-1\textgreek{a} were studied in 10 cases of ESCC treated with CCRT. The patients underwent CCRT between 2000 and 2010. The mean patient age was 68.1 years (range, 46-80 years). The numbers of patients in stages I, II, III and IV of the disease were 2, 2, 3 and 3, respectively. Of the tumors, 8 were positive for p53, 6 for p21\textsuperscript{waf1}, 7 for MIB-1 (Ki-67), 7 for p16\textsuperscript{INK4A}, 7 for cyclin D1, 8 for E-cadherin, 8 for Bcl-2, 0 for TNF-\textgreek{a}, 5 for NF-\textk{B}, 7 for TGF-\textgreek{B}, 7 for MMP-7, 7 for COX-2, 5 for EGFR, 1 for HER2/neu, 1 for ER and 7 for HIF-1\textgreek{a}. The 2-year overall survival rate of patients expressing high levels of MIB-1 was 71% (±17%) compared with 0% (P=0.019) for those expressing low levels. For NF-\textk{B}, the rate was 0% for patients with high levels compared with 100% (P<0.018) for those with low levels. The 2-year local control rates of HER2/neu were 0% in patients expressing high levels and 88% (±12%) in patients expressing low levels (P=0.027). The 2-year disease-free survival rates of HER2/neu and ER were 0% for patients expressing high levels compared with 56% (±17%) for those with low levels (P=0.027). There were no significant correlations between the expression levels of the other proteins and clinical outcomes. In the present study, high levels of MIB-1 and low levels of NF-\textk{B}, HER2 and ER were shown to be good prognostic factors following definitive CCRT for ESCC.

Introduction

Various investigators have studied the prognostic factors of esophageal squamous cell carcinoma (ESCC) treated with concurrent chemoradiation therapy (CCRT). In previous studies, it was considered that the expression levels of p53 (1-3), p21\textsuperscript{waf1} (4), molecular immunology borstel-1 (MIB-1) (2,5), p16\textsuperscript{INK4A} (6), cyclin D1 (2,7,8), E-cadherin (8), Bcl-2 (1), tumor necrosis factor (TNF)-\textgreek{a} (9), nuclear factor (NF)-\textk{B} (10), transforming growth factor (TGF)-\textgreek{B} (11), matrix metalloproteinase (MMP)-7 (12), cyclooxygenase (COX)-2 (13,14), epidermal growth factor receptor (EGFR) (15) and hypoxia-inducible factor (HIF)-1\textgreek{a} may be used as prognostic factors for ESCC. However, these studies included patients treated with surgery or neoadjuvant chemoradiation therapy (CRT). In the case of definitive CRT, the prognostic factors may be different from those of surgery or neoadjuvant CRT. Unlike surgical resection alone, which is not reliant on the therapeutic response, and neoadjuvant CRT, which is able to achieve complete responses in the majority of cases by resecting (even for cases without marked responses), in definitive CRT it is important to be able to predict therapeutic responses before starting treatment. Identifying predictive parameters may aid the selection of primary therapies. The present study was conducted using biopsy specimens excised from patients prior to CCRT. The expression levels of 16 proteins were analyzed to identify prognostic correlations in ESCC treated with CCRT.

Patients and methods

Patients. A total of 10 patients who received CCRT for ESCC at the University of Tokyo Hospital (Japan) between June 2000
and June 2010 were selected retrospectively. Only 10 patients (5 long-term survivors and 5 who had succumbed to cancer) were selected and examined, since this was a preliminary study to determine which type of immunostaining should be used in the following larger study. ESCC was confirmed histologically in all 10 patients. The patients consisted of 4 cases of good responses and 6 recurrent cases. The patients were staged according to the American Joint Committee for Cancer Staging and End Results Reporting 1997 staging system (17). The initial staging consisted of a patient history and medical examination, routine blood tests, chest X-rays, upper magnifying endoscopy, chest and upper abdomen computerized tomography (CT), barium contrast X-rays and pulmonary function tests. Bone scans and CT or magnetic resonance imaging of the brain were performed only in cases of clinical suspicion of metastases. Patients with technically unresectable cancer, patients who refused to undergo surgery or those considered medically unfit for surgery were eligible for definitive CCRT.

The study was approved by the ethics committee of the University of Tokyo, Tokyo, Japan. Informed consent was obtained from all patients or the patient’s families.

**CRT method.** The details of the treatment method have been previously reported (18-20). All patients received extended elective nodal irradiation and were treated with 50-50.4 Gy delivered at 1.8-2 Gy per fraction over 5-5.6 weeks. The clinical target volume (CTV) was defined as the whole thoracic esophagus (from the supra-clavicular fossae to the esophagogastric junction). The CTV comprised the M1a and regional lymph nodes (LNs), including positive LNs. The planning target volume was calculated by adding margins of 5-10 mm to the respective CTVs. The treatment planning was entirely 3-dimensional. At least 4 fields were used (2 anterior-posterior opposed fields and 2 anterior-posterior oblique opposed fields to remove the spinal cord from the radiation fields) and 1 or 2 beams were added using the field-in-field technique if necessary. Treatment was delivered by linear accelerators with 6-10 MV photons.

All patients received chemotherapy (CTX) concurrently with irradiation. The CTX consisted of 2 cycles of 5-fluorouracil (800 mg/m²/day, days 1-4 and 29-32), continuous with nedaplatin (80 mg/m², days 1 and 29, bolus) and standard techniques were used for hydration and alkalization. The CTX began on the first day of irradiation. After CCRT, in the adjuvant setting, an additional 1 or 2 cycles of the same doses of CTX were administered to patients who had sufficient bone marrow function and performance status and did not refuse additional CTX.

**Follow-up.** Patients were followed up on a regular basis, with visits at 1 month following treatment, every 3 months thereafter during the first 2 years and every 6 months thereafter. Chest X-rays were performed at every visit, while chest and upper abdomen CT was performed every 6 months or more frequently at the suspicion of tumor progression. When tumor growth was identified by CT and/or PET, this was defined as local recurrence.

**Immunohistochemistry (IHC).** Specimens obtained from biopsies under endoscopy before the treatment were used. Tumor samples were fixed with 10% formaldehyde in phosphate-buffered saline (PBS), embedded in paraffin and 4-µm thick sections were prepared. The sections were deparaffinized and pretreated with various methods, including microwaving, EDTA and heating, that are known to be effective at unmasking reactive sites for antibodies. The characteristics of the 16 primary antibodies used in IHC and their pretreatments are shown in Table I. Subsequently, IHC staining was performed with an automated IHC stainer. The slides were then rinsed briefly in water and counterstained with haematoxylin.

The level of expression was assessed semi-quantitatively using the immunoreactive scoring (IRS) system (21). The IRS score was determined by considering the intensity, graded on a scale of 0-3 (0 = no staining, 1 = weak staining, 2 = moderate staining and 3 = marked staining) and extent (percentage of positive tumor cells) of staining. The extent of staining was graded on a scale of 0-4 (0 = no staining; 1 = 1-10% staining, 2 = 11-50% staining, 3 = 51-80% staining and 4 = 81-100% staining). The IRS score (range, 0-12) was the product obtained by multiplying the intensity and extent of staining.

The IRS scores from 0-12 were interpreted as follows: 0, negative; 1-4, weak; 5-8, moderate; and 9-12, markedly positive.

The low and high cut-off values for the scores of the biochemical markers were established as follows: i) p53, p16/INKA, cyclin D1, E-cadherin, TGF-β, MMP-7, COX-2, EGFR and HIF-1α: low, 0-2; high, 3-12; ii) Bcl-2 and HER2/neu: low, 0-8; high, 9-12; iii) MIB-1 (Ki-67): low, 0-3; high, 4-12; iv) p21 coding, estrogen receptor (ER) and TNF-α: low, 0-3; high, 4-12; and v) NF-κB: low, 0-11; high, 12.

**Statistical analysis.** Statistical analyses of the correlations between the clinical results (alive vs. deceased, with vs. without local recurrence and with vs. without disease) and molecular markers were performed using Fisher’s exact test. The association between each pair of proteins expressed was determined using the Pearson product-moment correlation coefficient.

The Kaplan-Meier product-limit method was used to estimate the probabilities of overall survival (OS), disease-free survival (DFS) and locoregional recurrence-free survival, while the log-rank test was used to estimate any differences. OS was calculated in months from the first day of CCRT to the date of mortality from any cause or to February 2012. Patients who remained alive in February 2012 were censored. P<0.05 was considered to indicate statistically significant differences.

**Results**

**Patients.** The characteristics of the 10 patients are shown in Table II. The median age was 68.1 years (range, 46-80 years). The sub-sites of the primary tumors included the middle (n=2) or lower (n=8) thoracic portions. The TNM classifications were as follows: T1/T2/T3/T4, 2/3/5/0; N0/N1, 3/7; M0/M1a/M1b, 7/0/3; and stages I/II/III/IV, 2/2/3/3, respectively. The median follow-up for the 5 surviving patients was 76.2 (±24.8) months.

**IHC.** Staining evaluations, (negative, weak, moderate or marked for each of the 16 primary antibodies, were performed
Table I. Immunohistchemistry: characteristics of the primary antibodies.

| Protein  | Type     | Source                        | Pretreatment                      | Titer | Incubation | Staining        |
|----------|----------|-------------------------------|-----------------------------------|-------|------------|-----------------|
| p53      | Mouse MC | DO7 NCL-p53-DO7, Leica        | Microwave, 1 mM EDTA (pH 8.0)     | 1:200 | 30 min, 37°C | Nucleus         |
| p21<sup>wafl</sup> | Mouse MC | SNCL-WAF-1, Novocasra      | Heating (121°C, 15 min), citrate buffer (pH 6.0) | 1:100 | Overnight, 4°C | Nucleus         |
| MIB-1    | Mouse MC | MIB-1 M7240, DAKO             | Microwave, 1 mM EDTA (pH 8.0)     | 1:25  | 30 min, 37°C | Nucleus         |
| p16<sup>INK4A</sup> | Mouse MC | Z2117, Zeta                  | Heating (121°C, 15 min), citrate buffer (pH 6.0) | 1:200 | Overnight, 4°C | Cytoplasmic and nucleus |
| cyclin D1 | Rabbit MC | SP4 RM-9104-S, Thermo         | Microwave, 1 mM EDTA (pH 8.0)     | 1:250 | 30 min, 37°C | Cytoplasmic     |
| E-cadherin | Mouse MC | 36B5 NCL-E-Cad, Leica        | Microwave, 1 mM EDTA (pH 8.0)     | 1:25  | 30 min, 37°C | Membrane (cytoplasmic) |
| Bcl-2    | Mouse MC | 124 M0887, DAKO               | Microwave, 1 mM EDTA (pH 8.0)     | 1:80  | 30 min, 37°C | Cytoplasmic     |
| TNF-α    | Mouse MC | 2C8 sc-52250, Santa Cruz      | Heating (121°C, 20 min), citrate buffer (pH 6.4) | 1:100 | Overnight, 4°C | Cytoplasmic     |
| NF-κB    | Rabbit PC | Y241, Yanaihara              | Heating (121°C, 20 min), citrate buffer (pH 6.0), | 1:1000 | Overnight, 4°C | Cytoplasmic     |
| TGF-β1   | Rabbit PC | AB19135, Chemicon International | Microwave, 1 mM EDTA (pH 8.0)     | 1:200 | Overnight, 4°C | Cytoplasmic     |
| MMP-7    | Rabbit PC | 18515, IBL                   | Microwave, 1 mM EDTA (pH 8.0)     | 1:500 | Overnight, 4°C | Cytoplasmic     |
| COX-2    | Rabbit PC | K1492, DAKO                   | Microwave, 1 mM EDTA (pH 8.0)     | None  | 0.5 µg/ml, Overnight, 4°C | Cytoplasmic Membrane (cytoplasmic) |
| EGFR     | Mouse MC | K1492, DAKO                   | Proteinase K (kit) R-to-U | 30 min, RT | | |
| HER2     | Rabbit PC | K5204, DAKO                   | Water bath (99°C), citrate buffer (pH 6.0) | R-to-U | 30 min, RT | Membrane (cytoplasmic) |
| ER       | Mouse MC | 790-4325, Roche               | Microwave, 0.01 M citrate buffer (pH 6.0) | 1:100 | 60 min, RT | Membrane (cytoplasmic) |
| HIF-1α    | Rabbit PC | 07-628, MILLIPORE             | Microwave, 0.01 M citrate buffer (pH 6.0) | 1:200 | Overnight, 4°C | Nucleus         |

RT, room temperature; R-to-U, ready to use (kit); MC, monoclonal; PC, polyclonal; MIB-1, molecular immunology borstel-1; TNF-α, tumor necrosis factor-α; NF-κB, nuclear factor-κB; TGF-β, transforming growth factor-β; MMP-7, matrix metalloproteinase-7; COX-2, cyclooxygenase-2; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor type 2; ER, estrogen receptor; HIF-1α, hypoxia-inducible factor-1α; Leica, Mannheim, Germany; Novocasra, Newcastle upon Tyne, United Kingdom; DAKO, Carpinteria, CA, USA; Zeta, Sierra Madre, CA, USA; Thermo, Walthem, MA, USA; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA; Chemicon International, Temecula, CA, USA; IBL, Minneapolis, MN, USA; Roche, Mannheim, Germany; Millipore, Billerica, MA, USA.

**Clinical outcome.** Significant 2-year OS rates were observed for patients with high (MIB-1 IRS ≥9) and low (MIB-1 IRS <9) MIB-1 levels (71 vs. 0%, P=0.019; Fig. 1A) and high (NF-κB IRS = 12) and low (NF-κB IRS <12) NF-κB levels (0 vs. 100%, P<0.018; Fig. 1B). The correlations between the OS and expression levels of p53, p21<sup>wafl</sup>, p16<sup>INK4A</sup>, cyclin D1, E-cadherin, Bcl-2, TNF-α, TGF-β, MMP-7, COX-2, EGFR, HER2/neu, ER and HIF-1α were not found to be significant (Table III).

The 2-year local control rates were 0 vs. 88% (±12%, P=0.027; Fig. 1C) for patients with high (HER2/neu IRS ≥3, ER IRS ≥4) and low (HER2/neu IRS <3, ER IRS <4) levels of both HER2/neu and ER. The 2-year DFS rates of the same patients were 0 vs. 56% (±17%; P=0.027; Fig. 1D) and 0 vs. 80% (±18%; P=0.018; Fig. 1E) for patients with high and low levels of NF-κB, respectively. No significant correlations for the 10 patients. The results may be summarized as follows (with the numbers representing how many of the 10 patients showed expression for the antibody): a) negative: 1 p16<sup>INK4A</sup>, 4 Bcl-2, 4 TNF-α, 1 EGFR, 5 HER2/neu and 4 ER; b) Moderate: 1 p53, 1 p21<sup>wafl</sup>, 3 MIB-1 (Ki-67), 1 p16<sup>INK4A</sup>, 1 cyclin D1, 2 E-cadherin, 4 TGF-β, 4 MMP-7, 6 COX-2, 4 EGFR and 4 HIF-1α; c) Strong: 7 p53, 1 p21<sup>wafl</sup>, 7 MIB-1 (Ki-67), 6 p16<sup>INK4A</sup>, 7 cyclin D1, E-cadherin, 3 TGF-β, 6 MMP-7, 3 COX-2, 4 EGFR and 5 HIF-1α. In addition, correlation analysis revealed the following results with respect to the pairs of expression levels: p53 vs. cyclin D1, r=0.791, P=0.045; EGFR vs. p53, r=0.803, P=0.0034; MIB-1 vs. p21, r=0.752, P=0.0097; HER2 vs. ER, r=0.823, P=0.020; TNF-α vs. p21, r=0.739, P=0.012; TGF-β vs. COX-2, r=0.714, P=0.018; TGFβ vs. HIF-1α, r=0.730, P=0.014; and COX-2 vs. HIF-1α, r=0.794, P=0.0042.
were observed between the expression levels of the other 12 proteins and clinical outcomes (Table III).

Discussion

The clinical outcomes of 10 ESCC patients treated with radical CCRT were correlated with 16 molecular biomarkers. The present retrospective study was performed on patients treated between 2000 and 2010. A number of previous studies were designed for patients treated with radical surgery or preoperative CCRT (1-16). The present study is the first to conduct a comprehensive analysis of 16 proteins simultaneously in patients treated with definitive CCRT-alone. Additionally, the study showed for the first time that 4 biomarkers, including MIB-1, NF-κB, HER2 and ER, are prognostic factors for ESCC treated with CCRT.

In the present study, 10 patients were treated using a standard CCRT regimen. The 2-year OS, local control (LC) and DFS rates were all 50% and these results were comparable to previous reports (18-20). There was little difference in the clinical backgrounds between the 6 living and 4 deceased patients. In the cases of higher MIB-1 expression, the OS was significantly improved following definitive CCRT. In the cases with lower NF-κB expression, the OS and DFS rates were significantly improved following definitive CCRT. In the cases of lower HER2 and ER levels, the LC and DFS rates were significantly improved following definitive CCRT. TNF-α showed negative or extremely weak staining in all cases. There was no correlation between MIB-1 and NF-κB, which were independent prognostic factors. There was a strong correlation between HER2 and ER. All patients with high/low HER2 expression also expressed high/low ER. The results of the HER2 staining were entirely in accordance with those of ER.

MIB-1 monoclonal antibody recognizes proliferating cells in the G1, S, G2 and M phases of the cell cycle (22). The correlation between a high MIB-1 index and poor prognosis is well known in breast cancer (23). However, in the present study, in the cases of higher MIB-1 expression, the OS was significantly improved following definitive CCRT. Renzio et al. (5) concluded that the over-expression of MIB-1 was a significant factor for complete endoscopic response following CCRT in 56 patients with esophageal cancer, which is similar to the present results. The correlation between MIB-1 expression and a good response to CCRT is explained by the fact that MIB-1 expression is a marker of cellular proliferation.

NF-κB is a protein complex that controls the transcription of DNA. TNF-α and other transcription factors activate NF-κB. NF-κB activates interleukin (IL)-1 and others and is therefore involved in apoptosis or inflammation. Blocking NF-κB causes tumor cells to stop proliferating, die or become more sensitive to the action of antitumor agents. Thus, NF-κB is the subject of much active research among pharmaceutical companies as a target for anticancer therapy (24). Izzo et al (10) reported that activated NF-κB prior to therapy in 80 patients with esophageal cancer was associated with the lack of a complete pathological response, which supports the present result showing that patients with high expression levels of NF-κB had significantly poorer OS and DFS rates than those showing low levels.
Table III. Clinical outcome by the expression levels of biomarkers.

| IHC       | IRS score | 2-year No. | OS SD | 2-year P-value log-rank | 2-year LC SD | 2-year P-value log-rank | 2-year DFS SD | 2-year P-value log-rank |
|-----------|-----------|------------|-------|-------------------------|--------------|-------------------------|---------------|-------------------------|
| Bcl-2     | High      | 3-12       | 3     | 67 27                   | 0.55 67 27    | 0.19 67 27              | 0.85          |
|           | Low       | 0-2        | 7     | 43 19                   | 83 15        | 43 19                   |
| Cyclin D1 | High      | 6-12       | 7     | 43 19                   | 0.38 69 19   | <0.19 43 19             | 0.32          |
|           | Low       | 0-5        | 3     | 67 27                   | 100 0        | 67 27                   |
| E-cadherin| High      | 6-12       | 8     | 50 18                   | 0.76 73 17   | <0.90 50 18             | 0.75          |
|           | Low       | 0-5        | 2     | 50 35                   | 100 0        | 50 35                   |
| EGFR      | High      | 6-12       | 7     | 50 18                   | 0.57 80 18   | 0.75 60 22              | 0.67          |
|           | Low       | 0-5        | 5     | 40 22                   | 80 18        | 40 22                   |
| MIB-1     | High      | 9-12       | 7     | 71 17                   | 0.019* 71 17 | <0.83 71 17             | 0.90          |
|           | Low       | 0-8        | 3     | 0 0                     | 100 0        | 0 0                     |
| p53       | High      | 6-12       | 8     | 50 18                   | 0.76 73 17   | <0.98 50 18             | 0.75          |
|           | Low       | 0-5        | 2     | 50 35                   | 100 0        | 50 35                   |
| HER2      | High      | 3-12       | 1     | 0 0                     | 0.22 0 0     | 0.027* 0 0              | 0.027*        |
|           | Low       | 0-2        | 9     | 56 17                   | 88 12        | 56 17                   |
| ER        | High      | 4-12       | 1     | 0 0                     | 0.22 0 0     | 0.027* 0 0              | 0.027*        |
|           | Low       | 0-3        | 9     | 56 17                   | 88 12        | 56 17                   |
| p16INK4A  | High      | 6-12       | 7     | 50 18                   | 0.75 75 15   | <0.23 50 17             | 0.95          |
|           | Low       | 0-5        | 3     | 50 35                   | 100 0        | 50 35                   |
| TNF-α     | High      | 4-12       | 10    | - -                     | - - - -      | - - - -                 | - - - -       |
|           | Low       | 0-3        | 10    | - -                     | - - - -      | - - - -                 |
| p21waf1   | High      | 4-12       | 6     | 50 20                   | 0.70 67 19   | <0.16 50 20             | 0.65          |
|           | Low       | 0-3        | 4     | 50 25                   | 100 0        | 50 25                   |
| TGF-β     | High      | 6-12       | 7     | 44 17                   | <0.17 76 15  | 0.34 44 17              | 0.19          |
|           | Low       | 0-5        | 3     | 100 0                   | 100 0        | 100 0                   |
| NF-κB     | High      | 12         | 5     | 0 0                     | <0.0018* 53 25 | 0.11 0 0              | 0.0018*       |
|           | Low       | 0-11       | 5     | 100 0                   | 100 0        | 80 18                   |
| MMP-7     | High      | 6-12       | 9     | 44 17                   | <0.90 76 15  | <0.66 44 17             | <0.92         |
|           | Low       | 0-5        | 1     | 100 0                   | 100 0        | 0 0                     |
| COX-2     | High      | 6-12       | 7     | 43 19                   | 0.38 69 19   | 0.93 43 19              | 0.88          |
|           | Low       | 0-5        | 3     | 67 27                   | 100 0        | 67 27                   |
| HIF-1α    | High      | 6-12       | 7     | 29 17                   | <0.19 69 19  | 0.74 29 17              | 0.19          |
|           | Low       | 0-5        | 3     | 100 0                   | 100 0        | 67 27                   |

*p<0.05. IHC, immunohistochemistry; IRS, immunoreactive score; OS, overall survival; LC, local control; DFS, disease-free survival; SD, standard deviation. EGFR, epidermal growth factor receptor; MIB-1, molecular immunology borstel-1; HER2, human epidermal growth factor receptor type 2; ER, estrogen receptor; TNF-α, tumor necrosis factor-α; TGF-β, transforming growth factor-β; NF-κB, nuclear factor-κB; MMP-7, matrix metalloproteinase-7; COX-2, cyclooxygenase-2; HIF-1α, hypoxia-inducible factor-1α.
HER2 is a member of the EGFR family which is involved in the complex regulation of cell growth, proliferation and survival. HER2 protein has been implicated in the development of cancer. In addition to breast cancer, HER2 overexpression and gene amplification have also been reported in carcinomas of the colon, bladder, ovary, endometrium, lung, head and neck, esophagus and stomach (25). Akamatsu et al. (26) reported that HER2 immunostaining was suitable for predicting resistance to CRT in 34 patients with ESCC. Additionally, according to Mimura et al. (27), the survival rate of 66 patients with ESCC showing HER2 gene amplification was significantly worse than those without amplification.

The main function of ER is as a DNA-binding transcription factor regulating gene expression. Estrogen and ER have also been implicated in breast, ovarian, colon, prostate and endometrial cancer. Wang et al. (28) suggested that ER expression may predict a better outcome for patients with ESCC. These results concurred with the present results where patients showing high staining for HER2 and ER had significantly poorer LC and DRS rates than those with low staining. Estrogen promotes tumor proliferation through ER and in cells with overexpression of HER2, tumor proliferation is considered to be increased. The present result demonstrating that the prognosis of cases with overexpression of ER or HER2 was worse is therefore understandable.
In the present study, p53, p21waf1, p16INK4A, cyclin D1, E-cadherin, Bcl-2, TNF-α, TGF-β, MMP-7, COX-2, EGFR and HIF-1α were also investigated. The p53 gene is one of the well-known anti-oncogenes involved in apoptosis and the cell cycle (29-31). Also, the p21 and the p16INK4A proteins are involved in the cell cycle and induce G1 arrest. Cyclin D1 is a member of the cyclin protein family involved in regulating cell cycle progression. Bcl-2 is a member of the anti-apoptotic family (32,33). E-cadherin is important in cell adhesion and loss of E-cadherin function or expression has been implicated in cancer progression and metastasis. TGF-β is important in stopping the proliferation of normal epithelial cells and promoting the invasion of cancer cells. TNF, being an endogenous pyrogen, is able to induce fever, apoptotic cell death, sepsis through IL-1 and 6 production, cachexia and inflammation, as well as inhibit tumorigenesis and viral replication. The expression of COX-2 is induced by several stimuli, including growth factors, inflammation and cytokines. COX-2 is upregulated in numerous types of cancer (34). EGFR is the cell-surface receptor for epidermal growth factors and is a growth factor involved in the regulation of cell growth, proliferation and differentiation. Proteins of the MMP family are involved in the breakdown of the extracellular matrix in normal physiological processes, such as embryonic development, reproduction and tissue remodeling, as well as in disease processes, such as arthritis and metastasis (35). HIF-1α is a transcription factor that responds to changes in available oxygen in the cellular environment, particularly to decreases in oxygen or hypoxia (36). In the present study, these cancer growth-causing proteins did not appear to be prognostic factors for ESCC treated with CCRT.

However, the present study had a number of limitations. Firstly, the power may be poor since it involved only 10 patients in a retrospective setting. Secondly, the IHC method used was only able to examine protein expression levels and DNA mutation and amplification were not examined as with the polymerase chain reaction method.

We expect to continue these studies, thereby increasing the number of cases in a retrospective setting and confirming the conclusions of the present study.

In the present study, high levels of MIB-1 and NF-κB and low levels of HER2 and ER were good prognostic factors following definitive CCRT for ESCC. There was no significant correlation between the expression levels of the other proteins (p53, p21waf1, p16INK4A, cyclin D1, E-cadherin, Bcl-2, TNF-α, TGF-β, MMP-7, COX-2, EGFR and HIF-1α) and clinical outcomes.

References

1. Sarbia M, Stahl M, Fink U, Willers R, Seebert S and Gabbert HE: Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res 4: 2991-2997, 1998.
2. Takeuchi H, Ozawa S, Ando N, Kitagawa Y, Ueda M and Kitajima M: Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol 10: 792-800, 2003.
3. Makino T, Yamasaki M, Miyata H, Yoshioka S, Takiguchi S, Fujiwara Y, Nakajima K, Nishida T, Mori M and Doki Y: p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg Oncol 17: 804-811, 2010.
4. Ishida M, Morita M, Saeki H, Ogata T, Sadanaga N, Watanabe M, Kakeji Y and Machara Y: Expression of p53 and p21 and the clinical response for hyperthermochemo radiation in patients with esophageal squamous cell carcinoma of the esophagus. Anticancer Res 27: 3501-3506, 2007.
5. Ressiot E, Dahan L, Liprandi A, Giorgi R, Djourno XB, Padovani L, Aliberti S, Ries P, Laquière A, Laquière A, Thomas P and Seitz JP: Predictive factors of the response to chemoradiotherapy in esophageal cancer. Gastroenterol Clin Biol 32: 567-577, 2008.
6. Malik SM, Nevin DT, Cohen S, Hunt HL and Palazzone JP: Assay of immunohistochemistry for p61NKK4 and high-risk HPV DNA by in situ hybridization in esophageal squamous cell carcinoma. Int J Surg Pathol 19: 31-34, 2011.
7. Sarbia M, Stahl M, Fink U, Heep H, Dutkowski P, Willers R, Seebert S and Gabbert HE: Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int J Cancer 84: 86-91, 1999.
8. No authors listed: Prognostic significance of CyclinDI and E-Cadherin in patients with esophageal squamous cell carcinoma: multinstitutional retrospective analysis, Research Committee on Malignancy of Esophageal Cancer, Japanese Society for Esophageal Diseases. J Am Coll Surg 192: 708-718, 2001.
9. Kuwahara A, Yamamori M, Fujita M, Okumo T, Tamura T, Kodama K, Okamura N, Nakamura T and Sakaida T: TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J Exp Clin Cancer Res 29: 100, 2010.
10. Zhao JP, Correa AM, Jelacic S, Malhotra U, Chao CK, Luthra R, Ensr J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB and Ajani JA: Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Thr 5: 2844-2850, 2006.
11. Pühringer-Oppermann F, Sarbia M, Ott N and Brücher BL: The predictive value of genes of the TGF-beta1 pathway in multid modally treated squamous cell carcinoma of the esophagus. Int J Colorectal Dis 25: 515-521, 2010.
12. Yamashita K, Mori M, Shiraiishi T, Shibuta K and Sugimachi K: Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 6: 1169-1174, 2000.
13. Takatori H, Natsugoe S, Okumura H, Matsumoto M, Ishigami S, Owaki T and Aikou T: Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma. Oncol Rep 13: 697-701, 2005.
14. Akutsu Y, Hânari N, Yamasu Y, Komatsu-Akimoto A, Ikeda N, Mori M, Yoneyama Y, Endo S, Miyazawa Y and Matsuura H: COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol 18: 396-405, 2011.
15. Gotoh M, Takuchi H, Kawabe S, Ohta S, Kii T, Kuwakado S and Kats K: Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma. Jpn J Clin Oncol 37: 652-657, 2007.
16. Ogawa K, Chiba I, Morioka T, Shimohji H, Tamaki W, Takamatsu R, Nishimaki T, Yoshimi N and Murayama S: Clinical significance of HIF-lalpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy. Anticancer Res 31: 2351-2359, 2011.
17. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG and Morrow M: AJCC Cancer Staging Handbook. 5th edition. Lippincott-Raven, Philadelphia, PA, 1997.
18. Yamashita H, Okuma K, Waki K, Kobayashi-Shibata S, Ohtomo K and Nakagawa K: Details of recurrence sites after elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) combined with concurrent thoracic hyperthermochemoradiotherapy squamous cell carcinoma - a retrospective analysis. Radiother Oncol 98: 255-260, 2011.
19. Yamashita H, Okuma K, Seto Y, Mori K, Kobayashi S, Waki K, Ohtomo K and Nakagawa K: A retrospective comparison of clinical outcomes and quality of life measures between definitive chemoradiation alone and radical surgery for clinical stage II-II esophageal carcinoma. J Surg Oncol 100: 435-441, 2009.
20. Yamashita H, Nakagawa K, Yamada K, Kaminishi M, Mafune K and Ohtomo K: A single institutional non-randomized retrospective comparison between definitive chemoradiotherapy and radical surgery in 82 Japanese patients with resectable esophageal squamous cell carcinoma. Dis Esophagus 21: 430-436, 2008.
21. Krajewska M, Krajewski S, Epstein JJ, Shabaik A, Sauvageot J, Song K, Kitada S and Reed JC: Immunohistochemical analysis of bcl-2, bax, bel-X, and mel-1 expression in prostate cancers. Am J Pathol 148: 1257-1276, 1996.

22. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000.

23. Yerushalmi R, Woods R, Ravdin PM, Hayes MM and Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183, 2010.

24. Escárcega RO, Fuentes-Alexandro S, García-Carrasco M, Gatica A and Zamora A: The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol) 19: 154-61, 2007.

25. Koltz BR, Hicks DG and Whitney-Miller CL: HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options. Biotech Histochem 87: 40-45, 2012.

26. Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y, Tsurumaru M and Sasai K: c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 57: 1323-1327, 2003.

27. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A and Fuji H: Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 92: 1253-1260, 2005.

28. Wang QM, Yuan L, Qi YJ, Ma ZY and Wang LD: Estrogen analogues: promising target for prevention and treatment of esophageal squamous cell carcinoma in high risk areas. Med Sci Monit 16: HY19-HY22, 2010.

29. Lane DP: A death in the life of p53. Nature 362: 786-787, 1993.

30. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 Is a universal inhibitor of cyclin kinase. Nature 366: 701-704, 1993.

31. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE and Wang Y: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.

32. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.

33. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998.

34. Legan M: Cyclooxygenase-2, p53 and glucose transporter-1 as predictors of malignancy in the development of gallbladder carcinomas. Bosn J Basic Med Sci 10: 192-196, 2010.

35. Ii M, Yamamoto H, Adachi Y, Maruyama Y and Shinomura Y: Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 231: 20-27, 2006.

36. Smith TG, Robbins PA and Ratcliffe PJ: The human side of hypoxia-inducible factor. Br J Haematol 141: 325-334, 2008.